- Home
- GSHD vs GLPG Comparison
GSHD vs GLPG Comparison
Compare GSHD & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSHD
- GLPG
- Stock Information
- Founded
- GSHD 2003
- GLPG 1999
- Country
- GSHD United States
- GLPG Belgium
- Employees
- GSHD N/A
- GLPG N/A
- Industry
- GSHD Specialty Insurers
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- GSHD Finance
- GLPG Health Care
- Exchange
- GSHD Nasdaq
- GLPG Nasdaq
- Market Cap
- GSHD 2.2B
- GLPG 2.1B
- IPO Year
- GSHD 2018
- GLPG 2005
- Fundamental
- Price
- GSHD $67.14
- GLPG $34.69
- Analyst Decision
- GSHD Hold
- GLPG Sell
- Analyst Count
- GSHD 10
- GLPG 3
- Target Price
- GSHD $106.00
- GLPG $26.00
- AVG Volume (30 Days)
- GSHD 365.7K
- GLPG 199.1K
- Earning Date
- GSHD 10-22-2025
- GLPG 10-29-2025
- Dividend Yield
- GSHD 8.71%
- GLPG N/A
- EPS Growth
- GSHD 81.48
- GLPG N/A
- EPS
- GSHD 1.14
- GLPG N/A
- Revenue
- GSHD $340,762,000.00
- GLPG $323,674,692.00
- Revenue This Year
- GSHD $17.71
- GLPG $1.77
- Revenue Next Year
- GSHD $23.41
- GLPG $0.44
- P/E Ratio
- GSHD $59.42
- GLPG N/A
- Revenue Growth
- GSHD 23.70
- GLPG 5.43
- 52 Week Low
- GSHD $66.08
- GLPG $22.36
- 52 Week High
- GSHD $130.39
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- GSHD 24.95
- GLPG 55.45
- Support Level
- GSHD $66.08
- GLPG $32.37
- Resistance Level
- GSHD $73.43
- GLPG $37.78
- Average True Range (ATR)
- GSHD 2.67
- GLPG 0.85
- MACD
- GSHD -0.65
- GLPG 0.20
- Stochastic Oscillator
- GSHD 8.28
- GLPG 48.88
About GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.